Wedbush Reiterates Outperform on Vor Biopharma, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten reiterates an Outperform rating on Vor Biopharma (NASDAQ:VOR) and maintains an $11 price target.
March 21, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten reiterates an Outperform rating on Vor Biopharma and maintains an $11 price target.
The reiteration of an Outperform rating and maintenance of an $11 price target by a reputable analyst suggests a positive outlook on Vor Biopharma's stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100